Experimental stroke can also prevent Alzheimer's by "preventing the build up of toxic proteins in the brain." 19659003] Reduces inflammation and protects nerve cells and blood vessel lining
A test drug used to treat stroke can also prevent Alzheimer's research.
A study found to give the mouse the drug 3K3A-APC protects their brains from the build up of toxic proteins and inhibits memory loss. 3K3A APC has already been used to reduce bleeding in brain tissues in patients with tranquility, and trials have shown its safety.
drug used to treat stroke can also prevent Alzheimer's research suggests (stock)
research was conducted by the University of Southern California and led by Dr Berislav Zlokovic, director of the Zilkha Neurogenetic Institute at the Keck School of Medicine.
Alzheimer's is the most common form of dementia and affects more than 520,000 peo ple in the UK, according to the Alzheimer's Society.
The disease has about 5.7million patients in the US, Alzheimer's Association statistics show. 3K3A-APC is a genetically modified version of a human blood protein called activated protein C, the researchers explained in the Journal of Experimental Medicine.
Activated protein C reduces inflammation and protects nerve cells and the cells blood vessels from programmed cell suicide, known as apoptosis.
& # 39; Due to its neuroprotective, vascular and anti-inflammatory activities in several models of neurological disorders, we investigated whether 3K3A-APC can also protect the brain from the toxic effects of amyloid β-toxin in a mouse model of Alzheimer's disease. "Dr. Zlokovic said. Amyloid β proteins accumulate in the brain of Alzheimer's patients, leading to the progressive loss of nerve cells and reduced blood flow through the vital organ.
When injected into mice that were genetic. – the risk of Alzheimer's, the researchers found that 3K3A-APC reduced the accumulation of amyloid β by up to 50 percent over four months
This is compared to control rodents that did not receive 3K3A-APC and experienced cognitive decline, degradation of the blood brain barrier and neuroinflammation – a central element of Alzheimer's.  3K3A APC works by preventing nerve cells from producing the enzyme BACE1, which is necessary available to make amyloid β. Although inhibitors of BACE1 have been tested before, this study suggests blocking the production of the enzyme may be an effective approach, especially in the early stages of Alzheimer's before amyloid β permanently destroys the brain.
Our current data supports the idea that 3K3A-APC has potential as an effective anti-amyloid β therapy for early-stage Alzheimer's disease in humans, & # 39; said dr. Zlokovic.
3K3A-APC has already demonstrated strong safety in patients with sedation in clinical trials and in MS and brain trauma studies.
Based on the latest findings, Dr. Sara Imarisio, Research Director at Alzheimer's Research UK, MailOnline: "Having not had new dementia treatments for over 15 years, it is important that we continue to look at a number of angles to find a life-changing treatment for people with the condition.  & # 39; Amyloid remains one of the key targets for drug developers, but this is an early phase study with a substance not yet licensed for use in people who have had strokes.
& As with any research conducted by mice should be careful about how we analyze the results, and much more work is required before a drug like this could be resumed for use in people with Alzheimer's or any other neurodegenerative disease.
Professor Tara Spiers-Jones, head of the UK Dementia Research Institute Program added: "Dr. Zlokovic and his team published a very encouraging document showing that a drug called 3K3A-AP C prevents Alzheimer's-like symptoms in a mouse model of disease.
It's important to remember in the past many drugs that have similar beneficial effects in mouse models did not lead to improvements in people living with Alzheimer's.
& # 39; These experiments, however, open a promising path for future research into treatments to prevent Alzheimer's. & # 39;
WHAT IS ALZHEIMER?
Alzheimer's disease is a progressive, degenerative brain disorder where abnormal protein buildup causes nerve cells to die.
This interferes with transmitters carrying messages and causes the brain to shrink.
More than 5 million people suffer from the disease in the United States, where it is the 6th leading cause of death.
When brain cells die, the functions they give are lost.
It includes memory, orientation, and the ability to think and justify.
The course of the disease is slow and gradual.
On average, patients live five to seven years after diagnosis, but some may live for ten to 15 years.
- Short-term memory loss
- Behavioral changes
- Mood swings
- Difficulty managing money or calling
- Severe memory loss , forget about close family members, known objects or places
- Being worried and frustrated by the inability to make sense in the world, leading to aggressive behavior
- Eventually losing the ability to walk
- May have difficulty eating  The majority will eventually need 24-hour care
Source: Alzheimers Association